Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature

Thrombosis Research

Volumn 130, Issue 6, 2012, Pages 956-966

  Douxfils, Jonathan ^a   Mullier, François ^a,b   Loosen, Claire ^b   Chatelain, Christian ^b   Chatelain, Bernard ^b   Dogné, Jean Michel ^a  

^a UNIVERSITY OF NAMUR   (Belgium)

^b University of Namur   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; FIBRINOGEN; PROTEIN C; PROTEIN S; RECOMBINANT THROMBOPLASTIN; RIVAROXABAN; THROMBIN; THROMBOPLASTIN;

ABNORMAL LABORATORY RESULT; ACTIVATED PROTEIN C RESISTANCE; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; DRUG MONITORING; ENZYME ASSAY; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN TISSUE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; THROMBIN GENERATION ASSAY; THROMBOCYTE POOR PLASMA;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; HUMANS; MORPHOLINES; PROTHROMBIN TIME; THIOPHENES;

EID: 84870240173     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.09.004     Document Type: Article

References (48)

1. M.P. Gulseth, J. Michaud, and E.A. Nutescu Rivaroxaban: an oral direct inhibitor of factor Xa Am J Health Syst Pharm 65 2008 1520 1529
2. EMA. Xarelto-H-C-000944-II-0012: EPAR - Assessment Report - Variation. In: CHMP, editor. Accessed on 10th February 2012 http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Assessment-Report-Variation/human/000944/ WC500120735.pdf.
3. F.D.A. Approval History Accessed on 23th November 2011 http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202439s000lbl.pdf
4. E.M.A. Xarelto-H-C-000944-X-0010: EPAR - Assessment Report - Variation Accessed on 10th February 2012 http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Assessment-Report-Variation/human/000944/WC500120736.pdf
5. J.L. Mega, E. Braunwald, S.D. Wiviott, J.P. Bassand, D.L. Bhatt, and C. Bode Rivaroxaban in Patients with a Recent Acute Coronary Syndrome N Engl J Med 366 2011 9 19
6. A.T. Cohen, T.E. Spiro, H.R. Buller, L. Haskell, D. Hu, and R. Hull Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol J Thromb Thrombolysis 31 2011 407 416
7. A.G. Turpie, M.R. Lassen, B.I. Eriksson, M. Gent, S.D. Berkowitz, and F. Misselwitz Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies Thromb Haemost 105 2011 444 453
8. C.S. Miller, S.M. Grandi, A. Shimony, K.B. Filion, and M.J. Eisenberg Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation Am J Cardiol 110 2012 453 460
9. A. Banerjee, D.A. Lane, C. Torp-Pedersen, and G.Y. Lip Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study Thromb Haemost 107 2011
10. W. Mueck, L.C. Borris, O.E. Dahl, S. Haas, M.V. Huisman, and A.K. Kakkar Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement Thromb Haemost 100 2008 453 461
11. W. Mueck, A.W. Lensing, G. Agnelli, H. Decousus, P. Prandoni, and F. Misselwitz Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention Clin Pharmacokinet 50 2011 675 686
12. W. Mueck, B.I. Eriksson, K.A. Bauer, L. Borris, O.E. Dahl, and W.D. Fisher Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery Clin Pharmacokinet 47 2008 203 216
13. E.M.A. Summary of Product Characteristic (SmPC) Accessed on 23th January 2012 http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000944/WC500057108.pdf
14. D. Kubitza, M. Becka, W. Mueck, A. Halabi, H. Maatouk, and N. Klause Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor Br J Clin Pharmacol 70 2010 703 712
15. E. Nutescu, I. Chuatrisorn, and E. Hellenbart Drug and dietary interactions of warfarin and novel oral anticoagulants: an update J Thromb Thrombolysis 31 2011 326 343
16. A.K.D. Halabi, M. Zuehlsdorf, M. Becka, W. Mueck, and H. Maatouk Effect of hepatic impairment on the pharmacokinetics, pharmacodynamics and tolerability of rivaroxaban J Thromb Haemost 2007 (2007;5 Supplement 2:P-M-635)
17. H. Ten Cate Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb Haemost 107 2012
18. H. Bounameaux, and G. Reber New oral antithrombotics: a need for laboratory monitoring Against J Thromb Haemost 8 2010 627 630
19. P. Mismetti, and S. Laporte New oral antithrombotics: a need for laboratory monitoring For J Thromb Haemost 8 2010 621 626
20. Y.C. Barrett, Z. Wang, C. Frost, and A. Shenker Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay Thromb Haemost 104 2010 1263 1271
21. A. Hillarp, F. Baghaei, I.F. Blixter, K.M. Gustafsson, L. Stigendal, and M. Sten-Linder Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays J Thromb Haemost 9 2010 133 139
22. M.M. Samama, J.L. Martinoli, L. LeFlem, C. Guinet, G. Plu-Bureau, and F. Depasse Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor Thromb Haemost 103 2010 815 825
23. A. Tripodi, V. Chantarangkul, C. Guinet, and M.M. Samama The INR calibrated for Rivaroxaban-(INRrivaroxaban) has the potential to normalize PT results for Rivaroxaban-treated patients: results of an in-vitro study J Thromb Haemost 46 2010 520 527
24. J. Harenberg, S. Marx, R. Kramer, C. Giese, and C. Weiss Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban Blood Coagul Fibrinolysis 22 2011 637 641
25. M.M. Samama, G. Contant, T.E. Spiro, E. Perzborn, L.L. Flem, and C. Guinet Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial Clin Appl Thromb Hemost 18 2012 150 158
26. Y.C. Barrett, Z. Wang, and R.M. Knabb A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors Clin Appl Thromb Hemost Apr 2 2012 [Epub ahead of print]
27. L.M. Asmis, L. Alberio, A. Angelillo-Scherrer, W. Korte, A. Mendez, and G. Reber Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories Thromb Res. 129 2012 492 498
28. E. Lindhoff-Last, M.M. Samama, T.L. Ortel, J.I. Weitz, and T.E. Spiro Assays for measuring rivaroxaban: their suitability and limitations Ther Drug Monit 32 2010 673 679
29. E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, and K.H. Schlemmer In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor J Thromb Haemost 3 2005 514 521
30. G. Nowak The ecarin clotting time, a universal method to quantify direct thrombin inhibitors Pathophysiol Haemost Thromb 33 2003 173 183
31. S. Chia, E.M. Van Cott, O.C. Raffel, and I.K. Jang Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation Thromb Haemost 101 2009 535 540
32. T. Thenappan, R. Swamy, A. Shah, S. Nathan, J. Nichols, and L. Bond Interchangeability of Activated Clotting Time Values Across Different Point-of-Care Systems Am J Cardiol 109 2012 1379 1382
33. M.M. Samama, J. Amiral, C. Guinet, E. Perzborn, and F. Depasse An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma Thromb Haemost 104 2010 1078 1079
34. H. Mani, G. Rohde, G. Stratmann, C. Hesse, N. Herth, and S. Schwers Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin Thromb Haemost 108 2012
35. M.M. Samama, G. Contant, T.E. Spiro, E. Perzborn, C. Guinet, and Y. Gourmelin Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls Thromb Haemost 107 2012 379 387
36. S. Robert, J. Ghiotto, B. Pirotte, J.L. David, B. Masereel, and L. Pochet Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res 59 2009 160 166
37. G.T. Gerotziafas, F. Depasse, J. Busson, L. Leflem, I. Elalamy, and M.M. Samama Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay Thromb J 3 2005 16
38. H. Mani, C. Hesse, G. Stratmann, and E. Lindhoff-Last Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time Thromb Haemost 106 2011 156 164
39. B. Khor, and E.M. Van Cott Laboratory tests for antithrombin deficiency Am J Hematol 85 2010 947 950
40. V. Tichelaar, H. de Jong, H. Nijland, H. Kluin-Nelemans, K. Meijer, and A. Mulder Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays Thromb Haemost 106 2011 990 992
41. G.M. van Os, B. de Laat, P.W. Kamphuisen, J.C. Meijers, and P.G. de Groot Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time J Thromb Haemost 9 2011 1657 1659
42. G.T. Gerotziafas, H. Baccouche, M. Sassi, V. Galea, M. Chaari, and M. Hatmi Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban Thromb Res 129 2012 101 103
43. B. Goswami, D. Tayal, R. Chawla, and V. Mallika Pre-analytical factors that influence the interpretation of prothrombin time in the clinical laboratory: one year experience in a super speciality hospital in India Clin Chim Acta 410 2009 93 94
44. J.H. van Geest-Daalderop, and A.B. Mulder Boonman-de Winter LJ, Hoekstra MM, van den Besselaar AM. Preanalytical variables and off-site blood collection: influences on the results of the prothrombin time/international normalized ratio test and implications for monitoring of oral anticoagulant therapy Clin Chem 51 2005 561 568
45. A. Godier, A. Miclot, B. Le Bonniec, M. Durand, A.M. Fischer, and J. Emmerich Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model Anesthesiology 116 2012 94 102
46. G. Freyburger, G. Macouillard, S. Labrouche, and F. Sztark Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement Thromb Res 127 2011 457 465
47. G.T. Gerotziafas, I. Elalamy, F. Depasse, E. Perzborn, and M.M. Samama In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban J Thromb Haemost 5 2007 886 888
48. M.M. Samama, and C. Guinet Laboratory assessment of new anticoagulants Clin Chem Lab Med 49 2011 761 772